Mark J. Ratain to Germ-Line Mutation
This is a "connection" page, showing publications Mark J. Ratain has written about Germ-Line Mutation.
Connection Strength
0.556
-
The role of pharmacogenetics in cancer therapeutics. Br J Clin Pharmacol. 2006 Jul; 62(1):35-46.
Score: 0.234
-
Cancer pharmacogenomics: strategies and challenges. Nat Rev Genet. 2013 Jan; 14(1):23-34.
Score: 0.091
-
Functional EGFR germline polymorphisms may confer risk for EGFR somatic mutations in non-small cell lung cancer, with a predominant effect on exon 19 microdeletions. Cancer Res. 2011 Apr 01; 71(7):2423-7.
Score: 0.081
-
Global gene expression as a function of germline genetic variation. Hum Mol Genet. 2005 Jun 15; 14(12):1621-9.
Score: 0.054
-
Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015. Breast Cancer Res Treat. 2020 Jun; 181(3):623-633.
Score: 0.038
-
Analyzing the clinical actionability of germline pharmacogenomic findings in oncology. Cancer. 2018 07 15; 124(14):3052-3065.
Score: 0.033
-
Germline variants and advanced colorectal adenomas: adenoma prevention with celecoxib trial genome-wide association study. Clin Cancer Res. 2013 Dec 01; 19(23):6430-7.
Score: 0.024